HC Wainwright reissued their buy rating on shares of Edesa Biotech (NASDAQ:EDSA – Free Report) in a report released on Friday morning, Benzinga reports. HC Wainwright currently has a $21.00 price objective on the stock.
Edesa Biotech Price Performance
NASDAQ:EDSA opened at $4.28 on Friday. Edesa Biotech has a 12 month low of $2.46 and a 12 month high of $8.33. The business’s fifty day moving average price is $4.44 and its 200 day moving average price is $4.58.
Edesa Biotech (NASDAQ:EDSA – Get Free Report) last released its quarterly earnings data on Friday, May 10th. The company reported ($0.58) EPS for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.11. As a group, equities research analysts predict that Edesa Biotech will post -2 EPS for the current year.
About Edesa Biotech
Edesa Biotech, Inc, a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis.
Read More
- Five stocks we like better than Edesa Biotech
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Technology Stocks Explained: Here’s What to Know About Tech
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for Edesa Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edesa Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
